Evidence map›Paper›PMID 28297792›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2017

[Advances in basic and clinical research on hepatocellular carcinoma in 2016].

Z Z Dong, X D Zhu, Z Li, Y G Mao, Y L Chai, D F Yao, H C Sun, J Y Zhu, K S Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. [Cluster classification and clinical prognostic modeling based on m6A RNA methylation regulators in liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  2. [Expression of tuftelin protein and its clinical value in HBV-related liver cancer tissues].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Article
  3. [Effect of TUTF1 expression on the proliferation, apoptosis and prognosis of hepatocellular carcinoma cells].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Article
  4. [Estrogen and its receptors in hepatitis B virus-related hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2019
    Review
  5. [Clinical application of high mobility group box nuclear protein 1 subcomponent in the progression of liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  6. [Analysis of curative and prognostic effects of combined therapy of transarterial chemoembolization and sorafenib in hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  7. [Advances in the application of artificial intelligence in cancer diagnosis and treatment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  8. [Research advances in the mammalian target of rapamycin signaling pathway and its inhibitors in treatment of hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Review
  9. [Hepatitis B core antigen promotes invasion of hepatocellular carcinoma cell line HepG2.2.15 via Toll-like receptor 4].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017
    Article
  10. [The study of hepatocellular carcinoma molecular typing by high throughput sequencing of plasma cell free DNA].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017
    Article
  11. [A bioinformatics analysis of differentially expressed genes associated with liver cancer].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Z Z DongAffiliated Hospital of Nantong University, Nantong Jiangsu Province 226001, China.
X D ZhuDepartment of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Z LiDepartment of Hepatobiliary Surgery, Key Laboratory of Liver Cirrhosis and Cancer in Beijing, People's Hospital, Peking University, Beijing 100044, China.
Y G MaoDepartment of Hepatobiliary Surgery, Key Laboratory of Liver Cirrhosis and Cancer in Beijing, People's Hospital, Peking University, Beijing 100044, China.
Y L ChaiInstitute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
D F YaoAffiliated Hospital of Nantong University, Nantong Jiangsu Province 226001, China.
H C SunDepartment of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
J Y ZhuDepartment of Hepatobiliary Surgery, Key Laboratory of Liver Cirrhosis and Cancer in Beijing, People's Hospital, Peking University, Beijing 100044, China.
K S MaInstitute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is still one of common malignant cancers worldwide, with increasing incidence and mortality rates. Early diagnosis and effective treatment for HCC remain to be explored. This article introduces the research advances in the early specific diagnosis and effective therapies for HCC in 2016, such as molecular markers in the specific diagnosis and targeted therapy for HCC, main therapeutic regimens, robot-assisted liver resection, and no-touch radiofrequency ablation.

Indexed as

Biomedical ResearchCarcinoma, HepatocellularCatheter AblationHepatectomyHumansLiver NeoplasmsCarcinoma, hepatocellularDiagnosisMolecular markerRadiofrequency ablationRobertTherapeutics

Identifiers

PMID28297792
PMCPMC12814752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.